We will announce our financial results for the first six months of 2024 at 07:30 CEST on 07 August 2024.
We are pleased to announce our financial results for the first nine months of 2024 at 07:30 CET on 06 November 2024.
Q4 and full-year 2024 financial results will be published in the first two month of 2025. Exact date to be determined.
Our CEO, Lars Fruergaard Jørgensen, presented at the Annual J.P. Morgan Healthcare Conference in San Francisco, USA on 09 January.
Our Capital Markets Day took place on the 7th of March.
Novo Nordisk Executive Management and other members of senior management provided a full review of our strategy, operations and financial targets.
Our Annual General Meeting (AGM) will take place on 21 March 2024.
Stay tuned for upcoming events scheduled for 2024.
Q4
Novo Nordisk A/S announced financial results for the full year
of 2023:
Earnings conference call webcast
Q3
Earnings conference call webcast
London conference call webcast
Q2
Earnings conference call webcast
London conference call webcast
Q1
Annual General Meeting
23 March 2023
Annual General
Meeting (webcast)
Generalforsamling
(webcast)
See
previous AGM documentation
R&D investor call in relation to ADA 2023
26 June 2023
Presentation (Webcast)
Presentation (pdf)
American Heart Association (AHA) conference
11-12
November 2023
Capital Markets Day
03 March 2022
Watch the presentations and get the slides from the Novo Nordisk Capital Markets Day
Annual General Meeting
24 March 2022
Annual General Meeting (webcast)
See previous AGM documentation
5 June: Investor event (ADA 82nd Scientific Sessions)
Presentation (Webcast)
Presentation (pdf)
20 December: Conference call on supply situation for Wegovy®
28 June: R&D investor call
07 June: Approval of Wegovy™ in the US
21 May: International Operations call
25 March: Annual General Meeting
16 December: Decision to enter phase 3 development in Alzheimer’s disease and GLP-1 R&D strategy update
30 November: ESG conference call
9 October: Novo Nordisk raises sales and operating profit
outlook for 2020
19 June: R&D investor presentation
26 March: Annual General Meeting
Stay informed
Stay informed
Be the first one to read our company announcements and press releases. Sign up to Novo Nordisk News.
Investors
Share price
{{priceData.date}} {{priceData.time}}